Bruce A. Sullenger - Publications

Affiliations: 
Molecular Genetics and Microbiology Duke University, Durham, NC 
Area:
Molecular Biology, Cell Biology, Biochemistry

103 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Hu J, Hodgkinson CP, Pratt RE, Lee J, Sullenger BA, Dzau VJ. Enhancing cardiac reprogramming via synthetic RNA oligonucleotides. Molecular Therapy. Nucleic Acids. 23: 55-62. PMID 33335792 DOI: 10.1016/j.omtn.2020.10.034  0.32
2020 Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. Journal of Neurointerventional Surgery. PMID 33298508 DOI: 10.1136/neurintsurg-2020-016794  0.96
2019 Nimjee SM, Sullenger BA. Therapeutic Aptamers: Evolving to Find Their Clinical Niche. Current Medicinal Chemistry. PMID 31573879 DOI: 10.2174/0929867326666191001125101  0.96
2019 Nimjee SM, Dornbos D, Pitoc GA, Wheeler DG, Layzer JM, Venetos N, Huttinger A, Talentino SE, Musgrave NJ, Moody H, Rempel RE, Jones C, Carlisle K, Wilson J, Bratton C, ... ... Sullenger BA, et al. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30987839 DOI: 10.1016/j.ymthe.2019.03.016  0.96
2019 Moreno A, Pitoc GA, Ganson NJ, Layzer JM, Hershfield MS, Tarantal AF, Sullenger BA. Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. Cell Chemical Biology. PMID 30827937 DOI: 10.1016/j.chembiol.2019.02.001  0.36
2018 Darrabie MD, Cheeseman J, Limkakeng AT, Borawski J, Sullenger BA, Elster EA, Kirk AD, Lee J. Toll-like receptor activation as a biomarker in traumatically injured patients. The Journal of Surgical Research. 231: 270-277. PMID 30278940 DOI: 10.1016/j.jss.2018.05.059  0.32
2018 Huttinger AL, Wheeler DG, Gnyawali S, Dornbos D, Layzer JM, Venetos N, Talentino S, Musgrave NJ, Jones C, Bratton C, Joseph ME, Sen C, Sullenger BA, Nimjee SM. Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury. Journal of Visualized Experiments : Jove. PMID 30247470 DOI: 10.3791/57981  0.96
2018 Chabata CV, Frederiksen JW, Sullenger BA, Gunaratne R. Emerging applications of aptamers for anticoagulation and hemostasis. Current Opinion in Hematology. 25: 382-388. PMID 30015643 DOI: 10.1097/MOH.0000000000000452  0.36
2018 Gunaratne R, Kumar S, Frederiksen JW, Stayrook S, Lohrmann JL, Perry K, Bompiani KM, Chabata CV, Thalji NK, Ho MD, Arepally G, Camire RM, Krishnaswamy S, Sullenger BA. Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology. PMID 29863725 DOI: 10.1038/nbt.4153  0.68
2018 Naqvi I, Gunaratne R, McDade JE, Moreno A, Rempel RE, Rouse DC, Herrera SG, Pisetsky DS, Lee J, White RR, Sullenger BA. Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29550075 DOI: 10.1016/j.ymthe.2018.02.018  0.6
2017 Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA. Generation and characterization of aptamers targeting factor XIa. Thrombosis Research. 156: 134-141. PMID 28644959 DOI: 10.1016/j.thromres.2017.06.015  0.68
2017 Lee J, Lee Y, Xu L, White R, Sullenger BA. Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28372998 DOI: 10.1016/j.ymthe.2017.03.014  0.32
2017 Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as Therapeutics. Annual Review of Pharmacology and Toxicology. 57: 61-79. PMID 28061688 DOI: 10.1146/annurev-pharmtox-010716-104558  0.96
2016 Lee J, Jackman JG, Kwun J, Manook M, Moreno A, Elster EA, Kirk AD, Leong KW, Sullenger BA. Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. Biomaterials. 120: 94-102. PMID 28049065 DOI: 10.1016/j.biomaterials.2016.12.024  0.32
2016 Lee J, Xu L, Gibson TM, Gersbach CA, Sullenger BA. Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts. Biochemical and Biophysical Research Communications. PMID 27586271 DOI: 10.1016/j.bbrc.2016.08.159  0.32
2016 Kahsai AW, Wisler JW, Lee J, Ahn S, Cahill Iii TJ, Dennison SM, Staus DP, Thomsen AR, Anasti KM, Pani B, Wingler LM, Desai H, Bompiani KM, Strachan RT, Qin X, ... ... Sullenger BA, et al. Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. Nature Chemical Biology. PMID 27398998 DOI: 10.1038/nchembio.2126  1
2016 Sullenger BA, Nair S. From the RNA world to the clinic. Science (New York, N.Y.). 352: 1417-20. PMID 27313039 DOI: 10.1126/science.aad8709  1
2016 Mi J, Ray P, Liu J, Kuan CT, Xu J, Hsu D, Sullenger BA, White RR, Clary BM. In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9. Molecular Therapy. Nucleic Acids. 5: e315. PMID 27115840 DOI: 10.1038/mtna.2016.27  0.6
2016 Nimjee SM, Povsic TJ, Sullenger BA, Becker RC. Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Therapeutics. PMID 26882082 DOI: 10.1089/nat.2015.0581  0.96
2016 Lee Y, Urban JH, Xu L, Sullenger BA, Lee J. 2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors. Nucleic Acid Therapeutics. PMID 26789413 DOI: 10.1089/nat.2015.0575  0.32
2015 Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP, Hershfield MS. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. The Journal of Allergy and Clinical Immunology. PMID 26688515 DOI: 10.1016/j.jaci.2015.10.034  1
2015 Soule EE, Bompiani KM, Woodruff RS, Sullenger BA. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Therapeutics. PMID 26584417 DOI: 10.1089/nat.2015.0565  1
2015 Woodruff RS, Sullenger BA. Modulation of the Coagulation Cascade Using Aptamers. Arteriosclerosis, Thrombosis, and Vascular Biology. 35: 2083-91. PMID 26315404 DOI: 10.1161/ATVBAHA.115.300131  1
2015 Pratico ED, Feger BJ, Watson MJ, Sullenger BA, Bowles DE, Milano CA, Nair S. RNA-mediated reprogramming of primary adult human dermal fibroblasts into c-kit+ cardiac progenitor cells. Stem Cells and Development. PMID 26176491 DOI: 10.1089/scd.2015.0073  1
2014 Holl EK, Bond JE, Selim MA, Ehanire T, Sullenger B, Levinson H. The nucleic acid scavenger polyamidoamine third-generation dendrimer inhibits fibroblast activation and granulation tissue contraction. Plastic and Reconstructive Surgery. 134: 420e-33e. PMID 25158719 DOI: 10.1097/PRS.0000000000000471  1
2014 Bompiani KM, Lohrmann JL, Pitoc GA, Frederiksen JW, Mackensen GB, Sullenger BA. Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chemistry & Biology. 21: 935-44. PMID 25065530 DOI: 10.1016/j.chembiol.2014.05.016  1
2014 Kotula JW, Sun J, Li M, Pratico ED, Fereshteh MP, Ahrens DP, Sullenger BA, Kovacs JJ. Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. Plos One. 9: e93441. PMID 24736311 DOI: 10.1371/journal.pone.0093441  1
2013 Ray P, Sullenger BA, White RR. Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Nucleic Acid Therapeutics. 23: 435-42. PMID 24152208 DOI: 10.1089/nat.2013.0439  0.6
2013 Holl EK, Shumansky KL, Pitoc G, Ramsburg E, Sullenger BA. Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses. Plos One. 8: e69413. PMID 23936008 DOI: 10.1371/journal.pone.0069413  1
2013 Woodruff RS, Xu Y, Layzer J, Wu W, Ogletree ML, Sullenger BA. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. Journal of Thrombosis and Haemostasis : Jth. 11: 1364-73. PMID 23692437 DOI: 10.1111/jth.12302  1
2013 Pratico ED, Sullenger BA, Nair SK. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Therapeutics. 23: 35-43. PMID 23113766 DOI: 10.1089/nat.2012.0388  1
2013 Krishnan A, Vogler EA, Sullenger BA, Becker RC. The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. Journal of Thrombosis and Thrombolysis. 35: 48-56. PMID 23054460 DOI: 10.1007/s11239-012-0778-7  1
2012 Ray P, Cheek MA, Sharaf ML, Li N, Ellington AD, Sullenger BA, Shaw BR, White RR. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Therapeutics. 22: 295-305. PMID 23030589 DOI: 10.1089/nat.2012.0353  1
2012 Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, Leong KW, Lee J, Sullenger BA. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proceedings of the National Academy of Sciences of the United States of America. 109: 12938-43. PMID 22837404 DOI: 10.1073/pnas.1204928109  1
2012 Stearns NA, Lee J, Leong KW, Sullenger BA, Pisetsky DS. The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers. Plos One. 7: e40862. PMID 22808279 DOI: 10.1371/journal.pone.0040862  1
2012 Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Therapeutics. 22: 187-95. PMID 22703281 DOI: 10.1089/nat.2012.0347  1
2012 Ray P, Rialon-Guevara KL, Veras E, Sullenger BA, White RR. Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. The Journal of Clinical Investigation. 122: 1734-41. PMID 22484812 DOI: 10.1172/JCI62385  0.6
2012 Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. Journal of Thrombosis and Haemostasis : Jth. 10: 870-80. PMID 22385910 DOI: 10.1111/j.1538-7836.2012.04679.x  1
2012 Bompiani KM, Woodruff RS, Becker RC, Nimjee SM, Sullenger BA. Antidote control of aptamer therapeutics: the road to a safer class of drug agents. Current Pharmaceutical Biotechnology. 13: 1924-34. PMID 22352726 DOI: 10.2174/138920112802273137  1
2012 Sullenger B, Woodruff R, Monroe DM. Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. The Journal of Biological Chemistry. 287: 12779-86. PMID 22334679 DOI: 10.1074/jbc.M111.300772  1
2012 Pisetsky DS, Lee J, Leong KW, Sullenger BA. Nucleic acid-binding polymers as anti-inflammatory agents: reducing the danger of nuclear attack. Expert Review of Clinical Immunology. 8: 1-3. PMID 22149331 DOI: 10.1586/eci.11.82  1
2012 Nimjee SM, Lohrmann JD, Wang H, Snyder DJ, Cummings TJ, Becker RC, Oney S, Sullenger BA. Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 391-7. PMID 22086230 DOI: 10.1038/mt.2011.226  1
2012 Rangnekar A, Zhang AM, Li SS, Bompiani KM, Hansen MN, Gothelf KV, Sullenger BA, LaBean TH. Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 673-81. PMID 21889476 DOI: 10.1016/j.nano.2011.08.011  1
2011 Brandal S, Blake CM, Sullenger BA, Fortenberry YM. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Therapeutics. 21: 373-81. PMID 22103403 DOI: 10.1089/nat.2011.0320  1
2011 Lee J, Sohn JW, Zhang Y, Leong KW, Pisetsky D, Sullenger BA. Nucleic acid-binding polymers as anti-inflammatory agents. Proceedings of the National Academy of Sciences of the United States of America. 108: 14055-60. PMID 21844380 DOI: 10.1073/pnas.1105777108  1
2011 Burnette AD, Nimjee SM, Batchvarova M, Zennadi R, Telen MJ, Nishimura J, Sullenger BA. RNA aptamer therapy for vaso-occlusion in sickle cell disease. Nucleic Acid Therapeutics. 21: 275-83. PMID 21793788 DOI: 10.1089/nat.2010.0270  1
2011 Woodruff RS, Sullenger B, Becker RC. The many faces of the contact pathway and their role in thrombosis. Journal of Thrombosis and Thrombolysis. 32: 9-20. PMID 21404067 DOI: 10.1007/s11239-011-0578-5  1
2011 Blake CM, Wang H, Laskowitz DT, Sullenger BA. A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides. 21: 11-9. PMID 21142878 DOI: 10.1089/oli.2010.0262  1
2010 Povsic TJ, Sullenger BA, Zelenkofske SL, Rusconi CP, Becker RC. Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. Journal of Cardiovascular Translational Research. 3: 704-16. PMID 21080135 DOI: 10.1007/s12265-010-9230-6  0.56
2010 Becker RC, Povsic T, Cohen MG, Rusconi CP, Sullenger B. Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics Thrombosis and Haemostasis. 103: 586-595. PMID 20135076 DOI: 10.1160/TH09-10-0716  1
2010 Buddai SK, Layzer JM, Lu G, Rusconi CP, Sullenger BA, Monroe DM, Krishnaswamy S. An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. The Journal of Biological Chemistry. 285: 5212-23. PMID 20022942 DOI: 10.1074/jbc.M109.049833  1
2010 Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA, Clary BM. In vivo selection of tumor-targeting RNA motifs. Nature Chemical Biology. 6: 22-4. PMID 19946274 DOI: 10.1038/nchembio.277  1
2010 Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells (Dayton, Ohio). 28: 17-28. PMID 19921751 DOI: 10.1002/stem.261  1
2009 Nimjee SM, Oney S, Volovyk Z, Bompiani KM, Long SB, Hoffman M, Sullenger BA. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Rna (New York, N.Y.). 15: 2105-11. PMID 19846574 DOI: 10.1261/rna.1240109  1
2009 Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, Liu JY, Mack BC, Davis ME, Leong KW, Sullenger BA. Development of universal antidotes to control aptamer activity. Nature Medicine. 15: 1224-8. PMID 19801990 DOI: 10.1038/nm.1990  1
2009 Becker RC, Oney S, Becker KC, Sullenger B. Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. Annals of the New York Academy of Sciences. 1175: 61-70. PMID 19796078 DOI: 10.1111/j.1749-6632.2009.05017.x  1
2009 Zhou J, Soontornworajit B, Martin J, Sullenger BA, Gilboa E, Wang Y. A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. Macromolecular Bioscience. 9: 831-5. PMID 19434675 DOI: 10.1002/mabi.200900046  1
2009 Blake CM, Sullenger BA, Lawrence DA, Fortenberry YM. Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides. 19: 117-28. PMID 19284310 DOI: 10.1089/oli.2008.0177  1
2009 Liu Y, Sun QA, Chen Q, Lee TH, Huang Y, Wetsel WC, Michelotti GA, Sullenger BA, Zhang X. Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. Journal of Neurochemistry. 108: 147-57. PMID 19046328 DOI: 10.1111/j.1471-4159.2008.05748.x  1
2009 Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 153-61. PMID 18985031 DOI: 10.1038/mt.2008.235  1
2008 White RR, Roy JA, Viles KD, Sullenger BA, Kontos CD. A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function. Angiogenesis. 11: 395-401. PMID 19037734 DOI: 10.1007/s10456-008-9122-4  1
2008 Long SB, Long MB, White RR, Sullenger BA. Crystal structure of an RNA aptamer bound to thrombin. Rna (New York, N.Y.). 14: 2504-12. PMID 18971322 DOI: 10.1261/rna.1239308  1
2008 Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, Sullenger BA. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chemistry & Biology. 15: 675-82. PMID 18635004 DOI: 10.1016/j.chembiol.2008.05.016  1
2008 Dollins CM, Nair S, Sullenger BA. Aptamers in immunotherapy. Human Gene Therapy. 19: 443-50. PMID 18473674 DOI: 10.1089/hum.2008.045  1
2008 Viles KD, Sullenger BA. Proximity-dependent and proximity-independent trans-splicing in mammalian cells. Rna (New York, N.Y.). 14: 1081-94. PMID 18441053 DOI: 10.1261/rna.384808  1
2008 Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair S. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 125: 229-40. PMID 18393968 DOI: 10.1111/j.1365-2567.2008.02833.x  1
2008 McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. The Journal of Clinical Investigation. 118: 376-86. PMID 18060045 DOI: 10.1172/JCI33365  1
2008 Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. The Journal of Surgical Research. 146: 16-23. PMID 17950331 DOI: 10.1016/j.jss.2007.04.028  1
2008 Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, Dewhirst MW, Sullenger BA, Kontos CD, Clary BM. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 66-73. PMID 17912235 DOI: 10.1038/sj.mt.6300320  1
2008 Hong SH, Jeong JS, Lee YJ, Jung HI, Cho KS, Kim CM, Kwon BS, Sullenger BA, Lee SW, Kim IH. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 74-80. PMID 17700543 DOI: 10.1038/sj.mt.6300282  0.48
2008 Blake CM, Oney S, Nimjee SM, Sullenger BA. Aptamers and siRNAs in cardiovascular disease Rna Technologies in Cardiovascular Medicine and Research. 255-287. DOI: 10.1007/978-3-540-78709-9_13  1
2007 Oney S, Nimjee SM, Layzer J, Que-Gewirth N, Ginsburg D, Becker RC, Arepally G, Sullenger BA. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides. 17: 265-74. PMID 17854267 DOI: 10.1089/oli.2007.0089  1
2007 Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER, Layzer JM, Keys JR, Hagen PO, Nevins JR, Koch WJ, Sullenger BA. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America. 104: 12988-93. PMID 17652516 DOI: 10.1073/pnas.0704754104  1
2007 Kierlin-Duncan MN, Sullenger BA. Using 5'-PTMs to repair mutant beta-globin transcripts. Rna (New York, N.Y.). 13: 1317-27. PMID 17556711 DOI: 10.1261/rna.525607  1
2006 McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnology. 24: 1005-15. PMID 16823371 DOI: 10.1038/nbt1223  1
2006 Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 408-15. PMID 16765093 DOI: 10.1016/j.ymthe.2006.04.006  1
2006 Nimjee SM, Rusconi CP, Sullenger BA. Aptamers to Proteins The Aptamer Handbook: Functional Oligonucleotides and Their Applications. 131-166. DOI: 10.1002/3527608192.ch6  1
2005 Mi J, Zhang X, Giangrande PH, McNamara JO, Nimjee SM, Sarraf-Yazdi S, Sullenger BA, Clary BM. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochemical and Biophysical Research Communications. 338: 956-63. PMID 16256939 DOI: 10.1016/j.bbrc.2005.10.043  1
2005 Jones JP, Kierlin MN, Coon RG, Perutka J, Lambowitz AM, Sullenger BA. Retargeting mobile group II introns to repair mutant genes. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 687-94. PMID 15851007 DOI: 10.1016/j.ymthe.2005.01.014  1
2005 Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends in Cardiovascular Medicine. 15: 41-5. PMID 15795162 DOI: 10.1016/j.tcm.2005.01.002  1
2005 Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annual Review of Medicine. 56: 555-83. PMID 15660527 DOI: 10.1146/annurev.med.56.062904.144915  1
2004 Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G, Scardino E, Fay WP, Sullenger BA. Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnology. 22: 1423-8. PMID 15502817 DOI: 10.1038/nbt1023  1
2004 Potti A, Rusconi CP, Sullenger BA, Ortel TL. Regulatable aptamers in medicine: focus on antithrombotic strategies. Expert Opinion On Biological Therapy. 4: 1641-7. PMID 15461575 DOI: 10.1517/14712598.4.10.1641  0.48
2004 Shin KS, Sullenger BA, Lee SW. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 365-72. PMID 15294183 DOI: 10.1016/j.ymthe.2004.05.007  0.48
2004 Jeter ML, Ly LV, Fortenberry YM, Whinna HC, White RR, Rusconi CP, Sullenger BA, Church FC. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. Febs Letters. 568: 10-4. PMID 15196911 DOI: 10.1016/j.febslet.2004.04.087  0.6
2004 Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. Rna (New York, N.Y.). 10: 766-71. PMID 15100431 DOI: 10.1261/rna.5239604  1
2003 Nimjee SM, Sullenger BA. The Sabiston vision of basic science in a department of surgery. Annals of Surgery. 238: S28-32. PMID 14703741  1
2003 Byun J, Lan N, Long M, Sullenger BA. Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes. Rna (New York, N.Y.). 9: 1254-63. PMID 13130139 DOI: 10.1261/rna.5450203  1
2003 Long MB, Jones JP, Sullenger BA, Byun J. Ribozyme-mediated revision of RNA and DNA. The Journal of Clinical Investigation. 112: 312-8. PMID 12897196 DOI: 10.1172/JCI19386  1
2003 Sullenger BA, White RR, Rusconi CP. Therapeutic aptamers and antidotes: a novel approach to safer drug design. Ernst Schering Research Foundation Workshop. 217-23. PMID 12894459 DOI: 10.1007/978-3-662-05352-2_13  0.6
2003 White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger BA. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proceedings of the National Academy of Sciences of the United States of America. 100: 5028-33. PMID 12692304 DOI: 10.1073/pnas.0831159100  0.6
2002 Rogers CS, Vanoye CG, Sullenger BA, George AL. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. The Journal of Clinical Investigation. 110: 1783-9. PMID 12488428 DOI: 10.1172/JCI16481  1
2002 Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 419: 90-4. PMID 12214238 DOI: 10.1038/nature00963  0.48
2002 Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature. 418: 252-8. PMID 12110902 DOI: 10.1038/418252a  1
2002 Martell RE, Nevins JR, Sullenger BA. Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 30-4. PMID 12095300 DOI: 10.1006/mthe.2002.0624  1
2000 White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. The Journal of Clinical Investigation. 106: 929-34. PMID 11032851 DOI: 10.1172/JCI11325  0.6
2000 Lan N, Rooney BL, Lee SW, Howrey RP, Smith CA, Sullenger BA. Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 245-55. PMID 10985955 DOI: 10.1006/mthe.2000.0125  0.48
1999 Long MB, Sullenger BA. Evaluating group I intron catalytic efficiency in mammalian cells. Molecular and Cellular Biology. 19: 6479-87. PMID 10490588  1
1998 Lan N, Howrey RP, Lee SW, Smith CA, Sullenger BA. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science (New York, N.Y.). 280: 1593-6. PMID 9616120 DOI: 10.1126/science.280.5369.1593  1
1991 Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation Journal of Virology. 65: 6811-6816. PMID 1942253 DOI: 10.1128/jvi.65.12.6811-6816.1991  1
1990 Sullenger BA, Lee TC, Smith CA, Ungers GE, Gilboa E. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to moloney murine leukemia virus replication Molecular and Cellular Biology. 10: 6512-6523. PMID 2247070 DOI: 10.1128/MCB.10.12.6512  1
1990 Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication Cell. 63: 601-608. PMID 2225067 DOI: 10.1016/0092-8674(90)90455-N  1
1989 Hantzopoulos PA, Sullenger BA, Ungers G, Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector Proceedings of the National Academy of Sciences of the United States of America. 86: 3519-3523. PMID 2542934 DOI: 10.1073/pnas.86.10.3519  1
Show low-probability matches.